Basic Info.

Survodutide (also known as BI 456906) is a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, jointly developed by Boehringer Ingelheim and Zealand Pharma, and is intended to treat metabolic diseases such as obesity and non-alcoholic steatohepatitis.

Survodutide is a drug with an innovative mechanism of action and is expected to become a potential option for the treatment of obesity and metabolic-related diseases. Multiple clinical studies are underway to evaluate its safety and efficacy.

---

Our factory

“Strength builds the foundation, and excellent services reach all over the world.” Create win-win situation with customers